RxDoctor Payments DataLook up a doctor →

Byung Ban, DO

Rheumatology · Lawrenceville, GANPI 1437512134

Payments from drug & device makers

$19,000in general payments, 2019–2025

Across 989 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Amgen$2K
  • Novartis$2K
  • UCB, Inc.$2K
  • Johnson & Johnson$1K
  • Mallinckrodt Hospital Products Inc.$899
  • plus $6K from 26 others

What the payments were for

  • Grants$2401%
  • Food & beverage$18,33597%
  • Education$4252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,000 in reported general payments places this provider in the 75th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$361,857
Medicare patients
101
Services billed
2,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept59$432,679
Humira(Cf) PenAdalimumab17$116,471
Orencia ClickjectAbatacept19$113,132
ForteoTeriparatide21$88,997
Cosentyx Sensoready (2 Pens)Secukinumab11$87,721
Cimzia (2 Pack)Certolizumab Pegol15$85,743
OrenciaAbatacept14$80,000
Actemra ActpenTocilizumab12$30,466
ProliaDenosumab14$24,541
Hydroxychloroquine Sulfate153$6,912
MethotrexateMethotrexate Sodium191$5,828
Entecavir18$4,851
Mycophenolate Mofetil27$4,660
Colchicine47$2,544
Diclofenac Sodium60$2,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo$322$88,99721 claims
UCB, Inc.Cimzia (2 Pack)$1,717$85,74315 claims
E.r. Squibb & Sons, L.L.C.Orencia$269$80,00014 claims
AmgenProlia$2,441$24,54114 claims
Scilex Pharmaceuticals Inc.Colchicine$33$2,54447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →